Tyrosine kinase inhibitors

From Libre Pathology
Jump to navigation Jump to search

Tyrosine kinase inhibitors, abbreviated TKIs, are a group of drugs that inhibit the action of tyrosine kinases.

The category includes many cancer drugs - including:

  • Imatinib (Gleevec).
  • Gefitinib (Iressa).
  • Erlotinib (Tarceva).

Others - used in RCC:[1]

  • Sunitinib (Sutent).
  • Sorafenib (Nexavar).
  • Pazopanib (Votrient).


See also


  1. URL: http://dtb.bmj.com/content/49/11/129.abstract. Accessed on: 3 October 2014
  2. Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
  3. Elaidi, R.; Harbaoui, A.; Beuselinck, B.; Eymard, JC.; Bamias, A.; De Guillebon, E.; Porta, C.; Vano, Y. et al. (Feb 2015). "Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.". Ann Oncol 26 (2): 378-85. doi:10.1093/annonc/mdu552. PMID 25467013.
  4. Verma, J.; Jonasch, E.; Allen, P.; Tannir, N.; Mahajan, A. (Nov 2011). "Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.". Cancer 117 (21): 4958-65. doi:10.1002/cncr.26138. PMID 21484781.